ION537
/ Ionis, UT MD Anderson Cancer Center
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
July 04, 2025
Hippo/YAP signaling pathway in colorectal cancer: regulatory mechanisms and potential drug exploration.
(PubMed, Front Oncol)
- "Preclinical and clinical investigations highlight the efficacy of diverse Hippo/YAP-targeted interventions, with recent clinical trials (e.g., VT3989, IK-930, IAG933, ION537) underscoring the translational promise of this pathway. Integrating cutting-edge insights into its regulatory networks and clinical targeting offers novel perspectives for precision oncology. By bridging fundamental discoveries with translational applications, this review establishes Hippo/YAP as a compelling therapeutic target and provides a theoretical foundation for developing innovative CRC therapies."
Journal • Review • CNS Disorders • Colorectal Cancer • Oncology • Psychiatry • Solid Tumor • TAFAZZIN
December 21, 2022
A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=15 | Completed | Sponsor: Ionis Pharmaceuticals, Inc. | Recruiting ➔ Completed | N=102 ➔ 15 | Trial completion date: Jun 2023 ➔ Oct 2022 | Trial primary completion date: Jun 2023 ➔ Oct 2022
Enrollment change • Metastases • Trial completion • Trial completion date • Trial primary completion date • Oncology • Prostate Cancer • Solid Tumor • YAP1
1 to 2
Of
2
Go to page
1